Stockley’s Drug Interactions, edited by Claire L Preston, remains the world’s most comprehensive and authoritative international reference book on drug interactions and provides the busy healthcare professional with quick and easy access to clinically relevant, evaluated and evidence-based information on drug interactions.

Stockley’s Drug Interactions is a source book of interactions, their mechanisms, clinical importance and management. Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, foods, drinks, and drugs of abuse. Contains in-depth yet concise monographs in an easy-to-read format. Provides comprehensive details of the clinical evidence for the interactions under discussion, an assessment of their clinical importance, and clear guidance on managing the interaction in practice. Has a brief summary of the interaction in each monograph – perfect for the busy healthcare professional. Is fully referenced throughout. Contains almost 4500 monographs. Is global in coverage – inclusion of drugs used worldwide.

New in the 11th edition:

Over 350 new monographs added. Many existing monographs have been reviewed, revalidated, and updated. A comprehensive update and restructure of the chapter on Antidiabetic drugs, in-line with published literature. Addition of new advice regarding the concurrent use of aliskiren, ACE inhibitors, and angiotensin-II receptor antagonists. An updated list of drugs that have a risk of prolonging the QT interval. The addition of new drugs, including apixaban, apremilast, dutegravir, lomitapide, mirabegron, the NS5A inhibitors (daclatasvir, ledipasvir, ombitasvir), the NS5B inhibitors (dasabuvir, sofosbuvir), the sodium-glucose co-transporter-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), and telavancin.